CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
走得多与走得少的路——探讨 B 细胞 ALL 中 CAR-T 细胞治疗后巩固性异基因造血干细胞移植的作用
英文原题：The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL.
查看英文原题
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向 CD19 的CAR-T 细胞治疗（CD19-CART）已提高复发和/或难治性 B 急性淋巴细胞白血病（ALL）儿童及成人患者的挽救治疗缓解率。然而，并非所有接受 CD19-CAR-T 细胞治疗的患者都能获得长期缓解。异基因造血干细胞移植作为巩固治疗的作用尚未明确。我们旨在综述迄今发表的相关文献，梳理提示 CD19-CART 治疗后 ALL 持久应答的预后标志物，以及治疗后复发的危险因素，从而识别可能从巩固性造血干细胞移植中获益的患者群体。
展开英文摘要原文
Treatment with CD19-targeted chimeric antigen receptor T cell therapy (CD19-CART) has improved salvage rates in children and adults with relapsed and/or refractory B-cell acute lymphoblastic leukemia (ALL).
However, not all patients treated with CD19-CAR T cells achieve long-term remission. The role of allogeneic hematopoietic stem cell transplantation as consolidative therapy remains undefined.
We aim to review the current literature published to date regarding prognostic markers indicating durable ALL response to CD19-CART and risk factors for relapse after CD19-CART to identify patient cohorts who may benefit from consolidative hematopoietic stem cell transplantation.
论文信息
- 作者
- Choe M、Summers C
- 第一作者单位
- Clinical Research Division, Fred Hutch Cancer Center, Seattle, Washington, USA; Department of Pediatrics, University of Washington, Seattle, Washington, USA.United States
- 通讯作者单位
- Department of Pediatrics, University of Washington, Seattle, Washington, USA; Seattle Children's Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA. Electronic address: corinne.summers@seattlechildrens.org.United States
- 文献类型
- 综述
- 期刊
- Seminars in hematology2024 Oct
- 原文标识
- PubMed 39370355 · DOI 10.1053/j.seminhematol.2024.08.004